

**Blue diode laser as supportive therapy for the management of vulvar
lichen sclerosus**

Serena Bergamo, Margherita Gobbo, Silvia Chimenton, Giorgia D'Angelo, Luca Guarda Nardini, Alessandro Gatti

SUPPLEMENTARY MATERIAL

Supplementary Table 1. Demographic data, disease duration, previous treatments, and comorbidities of patients enrolled in the study.

	Age (years)	Duration of LS	Previous therapies and outcomes	Comorbidities
Patient 1	80	>10 years	Clobetasole ointment: mild improvement	arterial hypertension, glaucoma
Patient 2	53	>10 years	Clobetasole ointment: ineffective; acitretin: mild improvement	Hereditary palmo-plantar cheratoderma
Patient 3	55	>10 years	Clobetasole ointment: ineffective, dapsone tablets: ineffective	Localized scleroderma of the trunk
Patient 4	70	>10 years	Clobetasole ointment: mild improvement; tacrolimus ointment: suspended for side effects (irritation)	arterial hypertension, autoimmune hypothyroidism, type 2 diabetes
Patient 5	58	between 5 and 10 years	Clobetasole ointment suspended for side effects (irritation); dapsone tablets suspended for lack of efficacy	arterial hypertension
Patient 6	58	between 5 and 10 years	Clobetasole ointment: mild improvement	arterial hypertension
Patient 7	51	<5 years	Clobetasole ointment suspended for lack of efficacy; tacrolimus ointment: mild improvement	none
Patient 8	58	between 5 and 10 years	Clobetasole ointment: mild improvement	autoimmune hypothyroidism
Patient 9	58	between 5 and 10 years	Clobetasole ointment: suspended for lack of efficacy	none

Patient 10	28	<5 years	Clobetasole ointment: mild improvement	none
Patient 11	62	between 5 and 10 years	Clobetasole ointment: mild improvement	none
Patient 12	58	<5 years	Clobetasole ointment: mild improvement	none